Revenue: As of FY2026, the actual value is USD 2.924 B.EPS: As of FY2026, the actual value is USD 1.EBIT: As of FY2026, the actual value is USD 240.53 M.<h4>Consolidated Results (Fiscal Year Ended March 31, 2026 vs. 2025)</h4><ul><li>Sales and other operating revenue: $2,924.5 million in fiscal year 2026, a 1% decrease from $2,947.3 million in fiscal year 2025.</li><li>Cost of goods sold: $2,412.5 million in fiscal year 2026, a 1% increase from $2,398.6 million in fiscal year 2025.</li><li>Gross profit margin: 17.5% in fiscal year 2026, a decrease of 110 basis points from 18.6% in fiscal year 2025.</li><li>Selling, general and administrative expenses: $300.7 million in fiscal year 2026, a 2% decrease from $305.3 million in fiscal year 2025.</li><li>Restructuring and impairment costs: $1.8 million in fiscal year 2026, an 83% decrease from $10.6 million in fiscal year 2025.</li><li>Goodwill Impairment: $41.1 million in fiscal year 2026, compared to $0 in fiscal year 2025.</li><li>Operating income (as reported): $168.5 million in fiscal year 2026, a 28% decrease from $232.8 million in fiscal year 2025.</li><li>Adjusted operating income (non-GAAP): $211.3 million in fiscal year 2026, a 13% decrease from $243.4 million in fiscal year 2025.</li><li>Net income attributable to Universal Corporation: $32.637 million in fiscal year 2026, compared to $95.047 million in fiscal year 2025.</li><li>Adjusted net income attributable to Universal Corporation (non-GAAP): $66.339 million in fiscal year 2026, compared to $116.332 million in fiscal year 2025.</li></ul><h4>Segment Results (Fiscal Year Ended March 31, 2026 vs. 2025)</h4><ul><li>Tobacco Operations sales and other operating revenues: $2,576.4 million in fiscal year 2026, a 1% decrease from $2,608.7 million in fiscal year 2025.</li><li>Tobacco Operations operating income: $211.5 million in fiscal year 2026, a 12% decrease from $240.2 million in fiscal year 2025.</li><li>Ingredients Operations sales and other operating revenues: $348.1 million in fiscal year 2026, a 3% increase from $338.6 million in fiscal year 2025.</li><li>Ingredients Operations operating income: $3.2 million in fiscal year 2026, a 74% decrease from $12.3 million in fiscal year 2025.</li></ul><h4>Operational Metrics</h4><ul><li>Inventory write-downs: $52.0 million, primarily of non-wrapper, dark air-cured tobacco, an increase of $32.2 million from the prior fiscal year.</li><li>Tobacco sales volumes and prices: Down 2% for the fiscal year, partially offset by higher third-party processing volumes and product mix.</li><li>Tobacco inventory write-downs (Tobacco Operations segment): $43.4 million, up $24.7 million.</li><li>Ingredients sales volumes: Increased, reflecting focus on solution-based products.</li><li>Uncommitted tobacco inventory levels: 27% at March 31, 2026, which is outside the target range due to delayed customer purchase commitments.</li><li>Oversupply positions: Flue-cured, burley, and some dark air-cured tobacco are in oversupply, while oriental tobacco is moving into a balanced position.</li></ul><h4>Cash Flow and Balance Sheet Items (Fiscal Year Ended March 31, 2026 vs. 2025)</h4><ul><li>Net cash provided by operating activities: $129.100 million in fiscal year 2026, compared to $326.974 million in fiscal year 2025.</li><li>Purchase of property, plant and equipment: - $48.829 million in fiscal year 2026, compared to - $62.601 million in fiscal year 2025.</li><li>Proceeds from sale of property, plant and equipment: $5.873 million in fiscal year 2026, compared to $3.783 million in fiscal year 2025.</li><li>Net cash used by investing activities: - $42.956 million in fiscal year 2026, compared to - $58.818 million in fiscal year 2025.</li><li>Net cash used by financing activities: - $284.343 million in fiscal year 2026, compared to - $63.235 million in fiscal year 2025.</li><li>Cash and cash equivalents at end of year: $62.178 million at March 31, 2026, compared to $260.115 million at March 31, 2025.</li><li>Total debt: $904.291 million at March 31, 2026, down $168.7 million from $1,072.957 million at March 31, 2025.</li><li>Net debt (non-GAAP): $845.489 million at March 31, 2026, up $28.9 million from $816.605 million at March 31, 2025.</li><li>Interest expense: $74.040 million in fiscal year 2026, down $5.6 million from $79.636 million in fiscal year 2025.</li><li>Available liquidity: Approximately $1.3 billion, consisting of cash and committed and uncommitted credit lines, as of March 31, 2026.</li><li>Pension settlement charge: $0 in fiscal year 2026, compared to $14.101 million in fiscal year 2025.</li><li>Effective tax rate: Higher for fiscal year 2026 due to various factors including the mix and timing of domestic and foreign earnings, discrete items, and tax deductibility of certain items.</li></ul><h4>Outlook / Guidance</h4>Universal Corporation expects market activity to help return uncommitted tobacco inventories to its targeted range during fiscal year 2027. The company is enhancing its Shank’s operation to drive efficiency and financial performance. Management is focused on execution, consistent progress, and sustainable value creation for shareholders.

Universal | 8-K: FY2026 Revenue: USD 2.924 B